Global Exosomes Market

Exosomes Market Size, Share, Growth Analysis, By Product (Kits & Reagents, Instruments), By Workflow (Isolation Methods, Downstream Analysis), By Application (Cancer, Cardiovascular Diseases (CVD)), By End-Use, By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2198 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 90 | Figures: 76

Exosomes Market Competitive Landscape

The Global Exosomes market is relatively fragmented, with a high level of competition. Companies are working on new product launches and other initiatives to provide better equipment to their customers and expand their companies globally. These industry leaders are expanding their client base in a variety of ways, and many organizations are forming strategic and creative partnerships with other start-up businesses in order to increase market share and profitability.

Exosomes Market Top Player's Company Profiles

  • QIAGEN (Germany) 
  • Takara Bio Company (Japan) 
  • Illumina, Inc. (USA) 
  • Thermo Fisher Scientific, Inc. (USA) 
  • Codiak Biosciences (USA) 
  • Exosome Diagnostics (USA) 
  • Evox Therapeutics (UK) 
  • ExCoBio Inc. (South Korea) 
  • Bio-Rad Laboratories Ltd. (USA) 
  • NanoSomix, Inc. (USA) 
  • System Biosciences (SBI) (USA) 
  • Lonza Group (Switzerland) 
  • Miltenyi Biotec (Germany) 
  • Norgen Biotek Corp. (Canada) 
  • AMS Biotechnology (AMSBIO) (UK) 
  • Creative Biolabs (USA) 
  • Capricor Therapeutics (USA) 
  • Aegle Therapeutics (USA) 
  • Anjarium Biosciences (Switzerland) 

Exosomes Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Exosomes Market size was valued at USD 250.8 million in 2022 and is poised to grow from USD 325.79 million in 2023 to USD 2641.25 million by 2031, growing at a CAGR of 29.9% during the forecast period (2024-2031). 

The Global Exosomes market is relatively fragmented, with a high level of competition. Companies are working on new product launches and other initiatives to provide better equipment to their customers and expand their companies globally. These industry leaders are expanding their client base in a variety of ways, and many organizations are forming strategic and creative partnerships with other start-up businesses in order to increase market share and profitability. 'QIAGEN (Germany) ', 'Takara Bio Company (Japan) ', 'Illumina, Inc. (USA) ', 'Thermo Fisher Scientific, Inc. (USA) ', 'Codiak Biosciences (USA) ', 'Exosome Diagnostics (USA) ', 'Evox Therapeutics (UK) ', 'ExCoBio Inc. (South Korea) ', 'Bio-Rad Laboratories Ltd. (USA) ', 'NanoSomix, Inc. (USA) ', 'System Biosciences (SBI) (USA) ', 'Lonza Group (Switzerland) ', 'Miltenyi Biotec (Germany) ', 'Norgen Biotek Corp. (Canada) ', 'AMS Biotechnology (AMSBIO) (UK) ', 'Creative Biolabs (USA) ', 'Capricor Therapeutics (USA) ', 'Aegle Therapeutics (USA) ', 'Anjarium Biosciences (Switzerland) '

Most pharmaceutical, biopharmaceutical, and medical device businesses make significant investments in the creation of new medications and equipment. The pharmaceutical sector invests much in R&D. Pharmaceutical businesses spend in R&D to provide the market with cutting-edge, high-quality goods. According to trends, the leading pharmaceutical firms are enhancing their R&D productivity by significant long-term expenditures in R&D as well as through joint R&D projects.

Exosomes can be used as a treatment platform for a variety of illnesses, including COVID-19. Exosomes are used in medicine to deliver therapeutic cargo components while avoiding immune rejection and cellular toxicity. They are cell-free options for treating a variety of illnesses and for tissue regeneration. Exosomal therapy for respiratory viral infections, including SARS-CoV-2, can be created because stem cell-derived exosomes are favorable in utilizing the anti-inflammatory and regenerative characteristics of parent cells.

The North American region holds the largest share of the market. The enhanced healthcare infrastructure, efficient government policies, presence of key players, and greater knowledge of diagnostics and healthcare among the populace are all factors that have contributed to the market expansion in this area. Due to a large number of government-funded research studies on the effects of exosome-based drugs on a variety of cancers, including melanoma, breast cancer, lung cancer, and pancreatic cancer, among others, and key players' collaboration with state universities in the area to conduct clinical trials in the United States, the species is likely to remain the most dominant country during the forecast period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Exosome Research Products Market
Buy Now GET FREE SAMPLE
Excipients Market
Buy Now GET FREE SAMPLE
Targeted Liposomes Drug Delivery Market
Buy Now GET FREE SAMPLE
Gelatin Market
Buy Now GET FREE SAMPLE
Membrane Market
Buy Now GET FREE SAMPLE
Microscopy Market
Buy Now GET FREE SAMPLE
Whole Exome Sequencing Market
Buy Now GET FREE SAMPLE
Enteric Softgel Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Exosomes Market

Report ID: SQMIG35H2198

$5,300
BUY NOW GET FREE SAMPLE